Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Antibody-drug Conjugate ABBV-399

Known as: ABBV-399 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
9023Background: c-Met overexpression (OE) and MET amplification (amp) are prognostic of poor outcome for non-small cell lung… Expand
Is this relevant?
2019
2019
3011Background: Telisotuzumab vedotin (ABBV-399; teliso-v [T]) is a c-Met–targeted antibody and MMAE drug conjugate. Activity of… Expand
Is this relevant?
2019
2019
9075Background: Lung-MAP is a platform trial to assess targeted therapies in SCC. S1400K was designed to evaluate the response to… Expand
Is this relevant?
2018
2018
PURPOSE This first-in-human study evaluated telisotuzumab vedotin (Teliso-V), formerly called ABBV-399, an antibody-drug… Expand
Is this relevant?
2017
2017
2509Background: The c-Met receptor is overexpressed in ~50% of pts with NSCLC. ABBV-399 is a first-in-class ADC composed of ABT… Expand
Is this relevant?
2016
2016
Purpose: Despite the importance of the MET oncogene in many malignancies, clinical strategies targeting c-Met have benefitted… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
2016
2016
2510Background: The c-Met receptor is overexpressed in multiple tumors. ABBV-399 is a first-in-class antibody-drug conjugate (ADC… Expand
Is this relevant?